MA33738B1 - Procédé de traitement de troubles prolifératifs et d'autres affections pathologiques médiés par bcr-abl, c-kit, ddr1, ddr2 ou l'activité kinase du pdgf-r - Google Patents
Procédé de traitement de troubles prolifératifs et d'autres affections pathologiques médiés par bcr-abl, c-kit, ddr1, ddr2 ou l'activité kinase du pdgf-rInfo
- Publication number
- MA33738B1 MA33738B1 MA34855A MA34855A MA33738B1 MA 33738 B1 MA33738 B1 MA 33738B1 MA 34855 A MA34855 A MA 34855A MA 34855 A MA34855 A MA 34855A MA 33738 B1 MA33738 B1 MA 33738B1
- Authority
- MA
- Morocco
- Prior art keywords
- ddr1
- ddr2
- bcr
- treatment
- proliferative disorders
- Prior art date
Links
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 101100498819 Caenorhabditis elegans ddr-1 gene Proteins 0.000 title 1
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 abstract 2
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 abstract 2
- 108010049959 Discoidins Proteins 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000027450 oncoproteins Human genes 0.000 abstract 1
- 108091008819 oncoproteins Proteins 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne un régime d'administration d'un pyrimidyl- aminobenzamide de formule (I) dans laquelle les radicaux sont tels que définis dans ce document, ou de l'un de ses sels pharmaceutiquement acceptables, pour le traitement de troubles prolifératifs, particulièrement des tumeurs solides et liquides, et d'autres affections pathologiques médiées par l'oncoprotéine Bcr-Abl, le récepteur de tyrosine kinase de la membrane cellulaire c-Kit, DDR1 (le récepteur 1 du domaine discoïdine), DDR2 (le récepteur 2 du domaine discoïdine) ou l'activité kinase du PDGF-R (récepteur du facteur de croissance d'origine plaquettaire), le pyrimidylaminobenzamide de formule I et, éventuellement, des supports pharmaceutiquement acceptables, étant dispersés dans une préparation fruitée.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26181209P | 2009-11-17 | 2009-11-17 | |
| PCT/US2010/056926 WO2011062927A1 (fr) | 2009-11-17 | 2010-11-17 | Méthode de traitement de troubles prolifératifs et d'autres affections pathologiques médiés par bcr-abl, c-kit, ddr1, ddr2 ou l'activité kinase du pdgf-r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33738B1 true MA33738B1 (fr) | 2012-11-01 |
Family
ID=43513643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34855A MA33738B1 (fr) | 2009-11-17 | 2012-05-11 | Procédé de traitement de troubles prolifératifs et d'autres affections pathologiques médiés par bcr-abl, c-kit, ddr1, ddr2 ou l'activité kinase du pdgf-r |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9061029B2 (fr) |
| EP (1) | EP2501384B2 (fr) |
| JP (2) | JP5829615B2 (fr) |
| KR (1) | KR101743315B1 (fr) |
| CN (1) | CN102612368B (fr) |
| AR (1) | AR079029A1 (fr) |
| AU (1) | AU2010322102B2 (fr) |
| BR (1) | BR112012011693A2 (fr) |
| CA (1) | CA2779490C (fr) |
| CL (1) | CL2012001270A1 (fr) |
| CO (1) | CO6551690A2 (fr) |
| DK (1) | DK2501384T4 (fr) |
| EC (1) | ECSP12011903A (fr) |
| ES (1) | ES2572128T5 (fr) |
| FI (1) | FI2501384T4 (fr) |
| GT (1) | GT201200150A (fr) |
| HR (1) | HRP20160472T4 (fr) |
| HU (1) | HUE027307T2 (fr) |
| IL (1) | IL219727A (fr) |
| JO (1) | JO3634B1 (fr) |
| MA (1) | MA33738B1 (fr) |
| ME (1) | ME02413B (fr) |
| MX (1) | MX2012005694A (fr) |
| MY (1) | MY169956A (fr) |
| NZ (1) | NZ599968A (fr) |
| PE (1) | PE20121476A1 (fr) |
| PH (1) | PH12012500965A1 (fr) |
| PL (1) | PL2501384T5 (fr) |
| RS (1) | RS54747B2 (fr) |
| RU (1) | RU2625835C2 (fr) |
| SG (1) | SG10201501169VA (fr) |
| SI (1) | SI2501384T2 (fr) |
| SM (1) | SMT201600143B (fr) |
| TN (1) | TN2012000206A1 (fr) |
| TW (1) | TWI498116B (fr) |
| WO (1) | WO2011062927A1 (fr) |
| ZA (1) | ZA201203328B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013068836A1 (fr) | 2011-11-07 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagoniste de ddr1 ou inhibiteur de l'expression génique de ddr1 destiné à être utilisé dans la prévention ou le traitement de la glomérulonéphrite rapidement progressive |
| JP6177768B2 (ja) | 2012-04-24 | 2017-08-09 | 中外製薬株式会社 | ベンズアミド誘導体 |
| HK1203943A1 (en) | 2012-04-24 | 2015-11-06 | 中外制药株式会社 | Quinazolinedione derivative |
| CA3134922A1 (fr) * | 2012-05-02 | 2013-11-07 | Georgetown University | Traitement d'une alpha-synucleinopathie au moyen d'inhibiteurs de la tyrosine kinase |
| PT2861579T (pt) * | 2012-05-15 | 2018-04-27 | Novartis Ag | Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl |
| US20140080772A1 (en) * | 2012-09-06 | 2014-03-20 | The Board Of Regents Of The University Of Texas System | Treatments for melanoma |
| US9561245B2 (en) | 2012-09-06 | 2017-02-07 | The Board Of Regents Of The University Of Texas System | Combination treatments for melanoma |
| US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| AU2014338070A1 (en) | 2013-10-23 | 2016-05-05 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
| TW201718474A (zh) * | 2015-08-31 | 2017-06-01 | 東麗股份有限公司 | 尿素衍生物及其用途 |
| CN108103186B (zh) * | 2018-02-28 | 2021-07-02 | 固安博健生物技术有限公司 | 诊断类风湿性关节炎和骨关节炎的分子标志物 |
| TWI770624B (zh) | 2018-06-15 | 2022-07-11 | 漢達生技醫藥股份有限公司 | 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途 |
| KR102902341B1 (ko) | 2018-11-20 | 2025-12-18 | 조지타운 유니버시티 | 신경 변성, 심근 변성 및 리소좀 축적 장애를 치료하기 위한 조성물 및 방법 |
| WO2020144649A1 (fr) * | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Composition pharmaceutique comprenant de l'enzalutamide dispersé dans une compote de pomme |
| IL295007A (en) | 2020-01-31 | 2022-09-01 | Nanocopoeia Llc | Amorphous nilotinib microparticles and uses thereof |
| CA3181361A1 (fr) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Comprime a desintegration orale comprenant une dispersion solide amorphe de nilotinib |
| JP2023543815A (ja) | 2020-09-29 | 2023-10-18 | シェンチェン ファーマシン シーオー．，エルティーディー． | 医薬組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04012845A (es) | 2002-06-28 | 2005-02-24 | Nippon Shinyaku Co Ltd | Derivado de amida. |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AU2003257963B2 (en) | 2002-08-01 | 2009-08-13 | Board Of Trustees Of The University Of Arkansas | Improved treatment of cancer with glutamine |
| PT1879585E (pt) | 2005-05-02 | 2013-07-23 | Novartis Ag | Utilização de derivados de pirimidilaminobenzamida para o tratamento de mastocitose sistémica |
| SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| EP1923053A1 (fr) | 2006-09-27 | 2008-05-21 | Novartis AG | Composition pharmaceutique comprenant de la nilotinib ou son sel |
| KR100925559B1 (ko) | 2007-10-26 | 2009-11-05 | 한국과학기술연구원 | 악티노마이신 ｄ를 유효성분으로 하는 ｄｄｒ과 콜라겐결합 저해제 |
-
2010
- 2010-11-14 JO JOP/2010/0396A patent/JO3634B1/ar active
- 2010-11-15 AR ARP100104212A patent/AR079029A1/es not_active Application Discontinuation
- 2010-11-16 TW TW099139425A patent/TWI498116B/zh active
- 2010-11-17 RS RS20160303A patent/RS54747B2/sr unknown
- 2010-11-17 RU RU2012124811A patent/RU2625835C2/ru active
- 2010-11-17 EP EP10781781.9A patent/EP2501384B2/fr active Active
- 2010-11-17 SI SI201031172T patent/SI2501384T2/sl unknown
- 2010-11-17 ES ES10781781T patent/ES2572128T5/es active Active
- 2010-11-17 HU HUE10781781A patent/HUE027307T2/hu unknown
- 2010-11-17 JP JP2012539982A patent/JP5829615B2/ja active Active
- 2010-11-17 HR HRP20160472TT patent/HRP20160472T4/hr unknown
- 2010-11-17 FI FIEP10781781.9T patent/FI2501384T4/fi active
- 2010-11-17 ME MEP-2016-89A patent/ME02413B/fr unknown
- 2010-11-17 DK DK10781781.9T patent/DK2501384T4/da active
- 2010-11-17 BR BR112012011693A patent/BR112012011693A2/pt not_active Application Discontinuation
- 2010-11-17 US US13/509,626 patent/US9061029B2/en active Active
- 2010-11-17 PH PH1/2012/500965A patent/PH12012500965A1/en unknown
- 2010-11-17 CN CN201080051819.0A patent/CN102612368B/zh not_active Ceased
- 2010-11-17 WO PCT/US2010/056926 patent/WO2011062927A1/fr not_active Ceased
- 2010-11-17 NZ NZ599968A patent/NZ599968A/en not_active IP Right Cessation
- 2010-11-17 MY MYPI2012001993A patent/MY169956A/en unknown
- 2010-11-17 PE PE2012000667A patent/PE20121476A1/es not_active Application Discontinuation
- 2010-11-17 MX MX2012005694A patent/MX2012005694A/es active IP Right Grant
- 2010-11-17 SG SG10201501169VA patent/SG10201501169VA/en unknown
- 2010-11-17 CA CA2779490A patent/CA2779490C/fr active Active
- 2010-11-17 PL PL10781781.9T patent/PL2501384T5/pl unknown
- 2010-11-17 AU AU2010322102A patent/AU2010322102B2/en active Active
- 2010-11-17 KR KR1020127012603A patent/KR101743315B1/ko active Active
-
2012
- 2012-05-07 TN TNP2012000206A patent/TN2012000206A1/en unknown
- 2012-05-08 ZA ZA2012/03328A patent/ZA201203328B/en unknown
- 2012-05-10 IL IL219727A patent/IL219727A/en active IP Right Grant
- 2012-05-11 MA MA34855A patent/MA33738B1/fr unknown
- 2012-05-16 CL CL2012001270A patent/CL2012001270A1/es unknown
- 2012-05-16 EC ECSP12011903 patent/ECSP12011903A/es unknown
- 2012-05-17 GT GT201200150A patent/GT201200150A/es unknown
- 2012-05-17 CO CO12081907A patent/CO6551690A2/es not_active Application Discontinuation
-
2015
- 2015-04-28 JP JP2015091857A patent/JP2015180636A/ja active Pending
-
2016
- 2016-05-23 SM SM201600143T patent/SMT201600143B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33738B1 (fr) | Procédé de traitement de troubles prolifératifs et d'autres affections pathologiques médiés par bcr-abl, c-kit, ddr1, ddr2 ou l'activité kinase du pdgf-r | |
| MA33666B1 (fr) | Procédé de traitement de troubles prolifératifs et d'autres états pathologiques à médiation par une activité kinase de bcr-abl, c-kit, ddr1, ddr2 ou pdgf-r | |
| MA31754B1 (fr) | Cis-imidazolines chirales | |
| MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| MA32314B1 (fr) | Inhibiteurs cycliques de la 11-beta-hydroxysteroide dehydrogenase 1 | |
| TN2015000168A1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA31117B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| MA35356B1 (fr) | Dérivés de 2-amino-4-(pyridine-2-yl)-5,6-dihydro-4h-1,3-oxazine, et leur utilisation comme inhibiteurs de bace1 et bace2 | |
| MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| TN2010000175A1 (fr) | Piperidino-dihydrothienopyrimidines substituees | |
| TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
| MA38080A1 (fr) | Dérivés substitués de phtalazin-1(2h)-one comme inhibiteurs sélectifs de la poly(adp-ribose) polymérase-1 | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA34234B1 (fr) | Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation | |
| TNSN05250A1 (fr) | Pyrimidinones substituees | |
| MA38138A1 (fr) | Dérivés inédits de quinolone | |
| MA38648B1 (fr) | Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| MA31567B1 (fr) | Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique | |
| MA38801B1 (fr) | Nouveaux composés isoindoline ou isoquinoléine, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
| MA37691B1 (fr) | 5-amino[1,4]thiazines comme inhibiteurs de bace1 | |
| MA37763A1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 | |
| Sweet et al. | The one-two punch: combination treatment in chronic myeloid leukemia | |
| EA201001180A1 (ru) | ЗАМЕЩЕННЫЕ 2-АМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |